Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Shares of Nurix Therapeutics rose after the company said it will receive a $15 million license extension fee from Sanofi for its STAT6 program. The stock climbed 11% to $11.76 on Monday. Shares have ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Sanofi has entered into an agreement to acquire Blueprint Medicines Corp., a U.S.-based biopharma company specializing in ...

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...